Prof. Dr. Sergi X. Trilla,
MD, MBA
Physician. Founder and CEO of trifermed.
My work began in medicine and developed through health industry leadership, entrepreneurship, teaching, investment and initiatives for Social Impact in Health.
Across these settings, my interest has remained the same: how can better understanding, decisions and collaboration contribute to better health?
In 2002, I founded trifermed with Marta Fernández. The company’s story and my own have developed together, shaped by the people and organisations with whom we have worked.
A perspective grounded in medicine.
My earliest clinical experience began while studying medicine in the late 1980s. Training and subsequent practice in Spain and the United Kingdom brought me close to decisions with direct consequences for people.
The Hippocratic commitment continues to inspire my work: bringing knowledge, experience and judgement into the service of those we seek to help.
| Period | Organisation | Experience |
|---|---|---|
| 1991–1994 | Clínica del Pilar Barcelona | Obstetrics and gynaecology trainee while studying medicine |
| Sep 1994–Sep 1996 | Hospital de Barcelona | Emergency care |
| Jun 1995–Sep 1996 | RACC | International medical emergency coordination |
| Sep 1996–Sep 1997 | NHS Birmingham | Senior House Officer in obstetrics and gynaecology |
| Sep 1997–Jun 1998 | RACC | International medical emergency coordination |
Working across hospital care and international medical assistance helped shape my understanding of responsibility, uncertainty and the practical conditions needed to care for people.
Experience inside health organisations.
My move into the pharmaceutical industry connected clinical experience with the organisational and commercial decisions that shape whether innovations can reach people.
International marketing, business development and executive responsibilities have exposed me to different stages of company development, from emerging biotechnology ventures to established and publicly listed organisations.
| Period | Organisation | Role |
|---|---|---|
| Jun 1998–Jun 1999 | Sanofi | Head of Medical Marketing Line |
| Jun 1999–Jun 2002 | Ferrer | International Marketing Director |
| Jun 2002–present | trifermed | Founder and CEO |
| May 2020–Oct 2024 | HIPRA | Senior Business Strategy Advisor Human Health Division |
| Jul 2021–Oct 2022 | Intrommune Therapeutics | Senior Strategic Partnerships Advisor (Jul–Oct 2021) · Chief Strategy Officer (Nov 2021–Oct 2022) |
| May 2022–Apr 2025 | Veru Inc. | Chief Business Officer |
| Feb 2024–Jul 2026 | Medisca | Senior Business Strategy Advisor |
Building trifermed.
I founded trifermed with Marta Fernández in 2002, following my experience in medicine and the pharmaceutical industry.
Over the years, our work has developed through international collaborations and the contributions of a team bringing different experience and perspectives to each decision. My own executive and advisory responsibilities have continued to inform that work.
Learning through teaching and mentoring.
Teaching and mentoring bring me into contact with different questions and ways of thinking. They allow me to share experience while continuing to challenge my own understanding.
| Period | Institution | Contribution |
|---|---|---|
| Sep 2008–Jun 2012 | Biocat | Teaching in business development for health solutions |
| Feb 2012–Dec 2021 | ESADE Business School | Adjunct Professor Entrepreneurship in Health |
| May 2020–present | ADA Forsyth Institute | Adjunct Faculty Entrepreneurship in Health |
| 2020–present | Universidad de Navarra | Visiting Professor, Pharmaceutical and Biotechnology Management Master’s Programme |
| 2013–present | Biocat d·Health Barcelona | Advisor and contributor: programme formation and subsequent contributions |
| 2026–present | Creative Destruction Lab | San Sebastián: Mentor, Quantum and AI Stream · Doha: Health Mentor |
An investor and evaluator perspective.
Working with investment communities and innovation programmes adds another perspective to the decisions founders and organisations face: what deserves commitment, what evidence is needed and what conditions can support progress.
| Period | Organisation | Contribution |
|---|---|---|
| Jan 2024–present | NewHealth Ventures | Investment committee Digital Health |
| Oct 2025–present | Medex Partners | Investor and Strategic Advisor |
| Feb 2026–present | Fundación la Caixa CaixaImpulse | Expert Evaluator Health Innovation |
Initiatives and commitments.
The commitment that began in medicine has found expression through initiatives I have helped create and organisations whose work I support.
The EIRA Movement
Founder & Steward. A journey beginning in 2005.
I initiated the Trifermed Social Evening in 2005, creating a space for people connected to health, entrepreneurship and society. The Trifermed Awards followed in 2015, recognising people and organisations contributing to Social Impact in Health.
EIRA carries this history forward as a philanthropic, social-impact and catalytic movement associated with trifermed, through Knowledge, Recognition and Community.
Explore the EIRA Movement (external site, opens in a new tab)Fundación GAEM
Vice Chair of the Board of Trustees · Since January 2026.
I support a foundation dedicated to advancing research and innovation in multiple sclerosis. GAEM received the Trifermed Award for Social Impact in Health in 2015.
Discover Fundación GAEM (external site, opens in a new tab)Fundació d’Oncologia Infantil Enriqueta Villavecchia
Ambassador · Since November 2022.
The foundation supports children and young people with serious illness and their families. My commitment as an ambassador followed its recognition at the Trifermed Awards in September 2022.
Discover the foundation (external site, opens in a new tab)Sharing experience through dialogue.
I contribute to conferences, teaching sessions and public conversations about health innovation, strategic decisions and collaboration.
| Year | Selected contribution |
|---|---|
| 2013 | CPhI Worldwide Frankfurt — partnerships in animal health; One Nucleus London — analysis for partnering |
| 2014 | MaRS Discovery District Toronto — partnerships for healthcare start-ups; Klifovet Munich — business modelling for veterinary medicinal products |
| 2014 | Bioemprenedor XXI Barcelona — partnering project methodology |
| 2015 | BIO KOREA — business modelling before partnering; Lessons Learned CataloniaBio and Biocat |
| 2026 | CPHI Milan — interview and public dialogue on health innovation |
Selected invited contributions also include Weill Cornell Medicine Qatar, HEC Paris, Northeastern University, UAB, UAM and other scientific and business programmes.
Education
Medicine and Surgery
Universitat Autònoma de Barcelona
1988–1994
MBA
Universitat de Barcelona
1997–1999
Artificial Intelligence: Implications for Business Strategy
MIT Sloan Executive Education and CSAIL
2024
Observations from Three Decades in Healthcare Innovation
The questions and lessons from this work are taking shape through essays and Strategic Case Essays, forming the foundations of a book.
Continue the conversation.
If your work raises a strategic question in health innovation, I would be pleased to hear from you.
Let’s talk